JP2022534846A5 - - Google Patents
Info
- Publication number
- JP2022534846A5 JP2022534846A5 JP2021561906A JP2021561906A JP2022534846A5 JP 2022534846 A5 JP2022534846 A5 JP 2022534846A5 JP 2021561906 A JP2021561906 A JP 2021561906A JP 2021561906 A JP2021561906 A JP 2021561906A JP 2022534846 A5 JP2022534846 A5 JP 2022534846A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- tmmp
- polypeptides
- amino acid
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025070050A JP2025118689A (ja) | 2019-05-29 | 2025-04-22 | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962854200P | 2019-05-29 | 2019-05-29 | |
| US62/854,200 | 2019-05-29 | ||
| US201962872048P | 2019-07-09 | 2019-07-09 | |
| US62/872,048 | 2019-07-09 | ||
| US201962901538P | 2019-09-17 | 2019-09-17 | |
| US62/901,538 | 2019-09-17 | ||
| PCT/US2020/034939 WO2020243315A1 (en) | 2019-05-29 | 2020-05-28 | Multimeric t-cell modulatory polypeptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025070050A Division JP2025118689A (ja) | 2019-05-29 | 2025-04-22 | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022534846A JP2022534846A (ja) | 2022-08-04 |
| JP2022534846A5 true JP2022534846A5 (OSRAM) | 2023-05-23 |
| JP7762068B2 JP7762068B2 (ja) | 2025-10-29 |
Family
ID=73552689
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561906A Active JP7762068B2 (ja) | 2019-05-29 | 2020-05-28 | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| JP2025070050A Withdrawn JP2025118689A (ja) | 2019-05-29 | 2025-04-22 | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025070050A Withdrawn JP2025118689A (ja) | 2019-05-29 | 2025-04-22 | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220017596A1 (OSRAM) |
| EP (1) | EP3976084A4 (OSRAM) |
| JP (2) | JP7762068B2 (OSRAM) |
| KR (1) | KR20220015382A (OSRAM) |
| CN (2) | CN114126635A (OSRAM) |
| AU (1) | AU2020282736B2 (OSRAM) |
| CA (1) | CA3137463A1 (OSRAM) |
| IL (1) | IL287192A (OSRAM) |
| MX (1) | MX2021014476A (OSRAM) |
| WO (1) | WO2020243315A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11505591B2 (en) * | 2016-05-18 | 2022-11-22 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR102760578B1 (ko) | 2016-12-22 | 2025-02-03 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| TW201920249A (zh) | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| AU2019401183A1 (en) * | 2018-12-19 | 2021-08-12 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| SG11202108346WA (en) | 2019-02-13 | 2021-08-30 | Beam Therapeutics Inc | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| CN115279398B (zh) | 2019-09-27 | 2025-07-04 | 比姆医疗股份有限公司 | 治疗液态癌症的组合物和方法 |
| EP4048402A4 (en) * | 2019-10-23 | 2023-11-22 | Cue Biopharma, Inc. | MODIFIED CYTOTOXIC T CELLS AND METHOD OF USE THEREOF |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| CA3212382A1 (en) * | 2021-03-19 | 2022-09-22 | Ronald D. Seidel Iii | T-cell modulatory polypeptides and methods of use thereof |
| EP4395769A1 (en) | 2021-09-01 | 2024-07-10 | Novartis AG | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| IL312485A (en) * | 2021-11-24 | 2024-07-01 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR20240116828A (ko) * | 2021-12-14 | 2024-07-30 | 씨디알-라이프 아게 | 이중 mhc-표적화 t 세포 관여자 |
| JP2025515575A (ja) * | 2022-04-14 | 2025-05-20 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞エンゲージングポリペプチドおよびその使用方法 |
| CN115838432B (zh) * | 2022-07-08 | 2023-12-08 | 浙江大学 | 一种靶向调控抗原特异性t细胞的融合蛋白及应用 |
| CN116063463B (zh) * | 2022-08-12 | 2025-08-01 | 辽宁成大生物股份有限公司 | 抗rHPV68 L1蛋白CD68单克隆抗体、rHPV68型蛋白抗原的检测试剂盒 |
| EP4577223A2 (en) * | 2022-08-26 | 2025-07-02 | Beam Therapeutics Inc. | Modified allogeneic cells and methods and compositions for the preparation thereof |
| CN120202015A (zh) | 2022-09-14 | 2025-06-24 | Cdr-生物科技股份有限公司 | Mage-a4肽双重t细胞衔接子 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE542137T1 (de) * | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
| ZA200810677B (en) * | 2006-05-19 | 2010-03-31 | Teva Pharma | Fusion proteins, uses thereof and processes for producing same |
| SI2519543T1 (sl) * | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| AU2013289881B2 (en) * | 2012-07-13 | 2018-01-18 | Zymeworks Bc Inc. | Multivalent heteromultimer scaffold design and constructs |
| WO2014096015A1 (en) * | 2012-12-21 | 2014-06-26 | F. Hoffmann-La Roche Ag | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
| EP3936521B1 (en) * | 2013-03-15 | 2026-02-11 | Xencor, Inc. | Heterodimeric proteins |
| PT3480213T (pt) * | 2014-06-18 | 2020-02-04 | Albert Einstein College Medicine | Polipéptidos syntac e utilizações dos mesmos |
| CA3014458A1 (en) * | 2016-03-02 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| AU2017225787B2 (en) * | 2016-03-03 | 2021-09-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN115073581A (zh) * | 2016-05-04 | 2022-09-20 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| US11505591B2 (en) * | 2016-05-18 | 2022-11-22 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR102760578B1 (ko) * | 2016-12-22 | 2025-02-03 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| US11851471B2 (en) * | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| IL269000B2 (en) * | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| US11407806B2 (en) * | 2017-04-06 | 2022-08-09 | Albert Einstein College Of Medicine | Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells |
| TW201920249A (zh) * | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| WO2022119958A1 (en) * | 2020-12-02 | 2022-06-09 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
-
2020
- 2020-05-28 AU AU2020282736A patent/AU2020282736B2/en active Active
- 2020-05-28 CA CA3137463A patent/CA3137463A1/en active Pending
- 2020-05-28 CN CN202080035915.XA patent/CN114126635A/zh active Pending
- 2020-05-28 JP JP2021561906A patent/JP7762068B2/ja active Active
- 2020-05-28 EP EP20815621.6A patent/EP3976084A4/en active Pending
- 2020-05-28 KR KR1020217037009A patent/KR20220015382A/ko active Pending
- 2020-05-28 WO PCT/US2020/034939 patent/WO2020243315A1/en not_active Ceased
- 2020-05-28 MX MX2021014476A patent/MX2021014476A/es unknown
- 2020-05-28 CN CN202410806389.2A patent/CN118852456A/zh active Pending
-
2021
- 2021-09-30 US US17/490,516 patent/US20220017596A1/en active Pending
- 2021-10-12 IL IL287192A patent/IL287192A/en unknown
-
2025
- 2025-04-22 JP JP2025070050A patent/JP2025118689A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548472A5 (OSRAM) | ||
| JP2020514375A5 (OSRAM) | ||
| JP2020533273A5 (OSRAM) | ||
| JP2021500855A5 (OSRAM) | ||
| CN110325205B (zh) | T细胞调节性多聚体多肽及其使用方法 | |
| JP2022515331A5 (OSRAM) | ||
| KR20220066075A (ko) | T-세포 조절 폴리펩타이드 및 이의 사용 방법 | |
| JP7282760B2 (ja) | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 | |
| JP2020511949A5 (OSRAM) | ||
| AU2021291405A1 (en) | Immune activating Fc domain binding molecules | |
| US20240067700A1 (en) | T-cell modulatory polypeptides and methods of use thereof | |
| JP2022536581A5 (OSRAM) | ||
| JP2017519491A5 (OSRAM) | ||
| JP2023500574A5 (OSRAM) | ||
| US20260053855A1 (en) | Modified Cytotoxic T Cells and Methods of Use Thereof | |
| CN113286621A (zh) | 多聚体t细胞调节多肽及其使用方法 | |
| JP2023512452A (ja) | Ｂｃｍａ指向性細胞免疫療法組成物および方法 | |
| JP2023500573A5 (OSRAM) | ||
| JP7742354B2 (ja) | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 | |
| US20240067699A1 (en) | T-cell modulatory polypeptides and methods of use thereof | |
| JP2024541334A5 (OSRAM) | ||
| US20250326813A1 (en) | Engineered interleukin-2 receptor beta reduced-binding agonist | |
| WO2015167948A1 (en) | Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies | |
| JP2024517658A5 (OSRAM) | ||
| US20260109958A1 (en) | T-Cell Modulatory Polypeptides and Methods of Use Thereof |